Phase III clinical studies demonstrate the superior outcomes by adding pertuzumab to a trastuzumab plus chemotherapy regimen in both metastatic and early-stage HER2+ BC (8, 9), leading to the US FDA approval of pertuzumab in conjunction with trastuzumab and chemotherapy in 2012. Here, ERBB2 is linked to breast cancer.